Heart:低危无症状人群动脉粥样硬化并非可忽略不计

2013-06-04 高晓方 译 医学论坛网

  韩国一项研究表明,在依据指南被分类为低危的无症状人群中,动脉粥样硬化斑块和显著狭窄的发病率并非可忽略不计;但考虑到这些患者的事件发生率较低,因此低危无症状的患者不应行CT血管造影(CCTA)检查。论文于5月30日在线发表于《心脏》(Heart)。   此项观察性研究共纳入4339例接受64排CCTA检查的序贯中年无症状受试者,其中2133例(49.2%)为NECP指南分类为低危的受试者。主要

  韩国一项研究表明,在依据指南被分类为低危的无症状人群中,动脉粥样硬化斑块和显著狭窄的发病率并非可忽略不计;但考虑到这些患者的事件发生率较低,因此低危无症状的患者不应行CT血管造影(CCTA)检查。论文于5月30日在线发表于《心脏》(Heart)。

  此项观察性研究共纳入4339例接受64排CCTA检查的序贯中年无症状受试者,其中2133例(49.2%)为NECP指南分类为低危的受试者。主要转归指标为动脉粥样硬化斑块、显著狭窄的发生率。

  结果显示,在2133例低危受试者中,11.4%(243例)受试者伴有动脉粥样硬化斑块,1.3%(28例)伴有冠脉显著狭窄,并且有0.8%(18例)伴有由非钙化斑块(NCP)导致的显著狭窄。冠脉显著狭窄受试者和由NCP导致的显著狭窄受试者中分别有75.0%和94.4%为年轻成人。中期随访显示4例受试者出现心脏事件:3例为需住院的不稳定性心绞痛,1例需接受经皮冠脉介入治疗。


The prevalence and characteristics of coronary atherosclerosis in asymptomatic subjects classified as low risk based on traditional risk stratification algorithm: assessment with coronary CT angiography

Objective To evaluate the prevalence and characteristics of coronary atherosclerosis in asymptomatic subjects classified as low risk by National Cholesterol Education Program (NCEP) guideline using coronary CT angiography (CCTA).

Design 

An observational study.

Setting 

A single tertiary referral centre.

Patients 

2133 (49.2%) subjects, who were classified as low risk by the NCEP guideline, of 4339 consecutive middle-aged asymptomatic subjects who underwent CCTA with 64-slice scanners as part of a general health evaluation.

Main outcome measures 

The incidence of atherosclerosis plaques, significant stenosis.

Results 

In the subjects at low risk, 11.4% (243 of 2133) of subjects had atherosclerosis plaques, 1.3% (28 of 2133) of subjects had significant stenosis, and 0.8% (18 of 2133) of subjects had significant stenosis caused by non-calcified plaque (NCP). Especially, 75.0% (21 of 28) of subjects with significant stenosis and 94.4% (17 of 18) of subjects with significant stenosis caused by NCP were young adults. Mid-term follow-up (29.3±14.9 months) revealed four subjects with cardiac events: three subjects with unstable angina requiring hospital stay and one subject with percutaneous coronary intervention.

Conclusions 

Although an asymptomatic population classified as low risk by the NCEP guideline has been regarded as a minimal risk group, the prevalence of atherosclerosis plaques and significant stenosis were not negligible. However, considering very low event rate for those patients, CCTA should not be performed in low-risk asymptomatic subjects, although CCTA might have the potential for identification of high-risk groups in the selected subjects regarded as a minimal-risk group by NCEP guideline.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944349, encodeId=0f2c194434950, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 22 11:13:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355763, encodeId=c3df1355e6318, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484920, encodeId=fc2f14849204f, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562161, encodeId=d74d15621616f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944349, encodeId=0f2c194434950, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 22 11:13:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355763, encodeId=c3df1355e6318, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484920, encodeId=fc2f14849204f, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562161, encodeId=d74d15621616f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=)]
    2013-06-06 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944349, encodeId=0f2c194434950, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 22 11:13:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355763, encodeId=c3df1355e6318, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484920, encodeId=fc2f14849204f, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562161, encodeId=d74d15621616f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1944349, encodeId=0f2c194434950, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 22 11:13:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355763, encodeId=c3df1355e6318, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484920, encodeId=fc2f14849204f, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562161, encodeId=d74d15621616f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 06 10:13:00 CST 2013, time=2013-06-06, status=1, ipAttribution=)]
    2013-06-06 slcumt

相关资讯

[OCC2013]稳定型冠心病的诊断策略:病情决定治疗决策

稳定型冠心病指的是斑块大部分是稳定的,如果无引起足够的狭窄或者冠脉血流受阻,那么患者应该以内科药物干预动脉粥样硬化,控制危险因素,加强他汀类治疗为主。临床实践以及临床研究均证实了他汀类药物、抗血小板药物、抗凝药物等药物能有效降低冠心病死亡率。但是所谓稳定与不稳定都是相对的,正如我们所说的运动和静止一样,不能偷换这个哲学的基本概念,其二,稳定型冠心病在一定程度上能转变成不稳定型冠心病,虽然稳定型冠心

Neurology:男性更常见狭窄性颈动脉斑块

  欧洲学者的一项研究表明。相当一部分青年卒中患者伴有动脉粥样硬化颈动脉狭窄和闭塞。论文于2013年3月6日在线发表于《神经病学》(Neurology)。   此项研究共纳入2187例卒中或短暂脑缺血发作(TIA)患者,其中男性为1319例,年龄为18至44岁者为744例。1612例(73.7%)患者接受附加颅内动脉超声检查。依据性别和年龄组(青年18~44岁;中年44~55岁)对患者进行分层。

JAMA:基于尸检的研究对美军中动脉粥样硬化的发病率进行了检查

据发表在12月26日出版的《美国医学会杂志》上的一项研究披露,在那些于2001-2011年间死于战斗或意外伤害并进行了尸体解剖的派驻美国军人中,冠状动脉粥样硬化的患病率为8.5%,与该疾病较高的患病率有关的因子包括:较大的年龄、较低的教育水平及先前确诊过的血脂异常、高血压及肥胖症。 马里兰州贝塞斯达国防医科大学的Bryant J. Webber, M.D.及其同事开展了一项研究,旨在评估美军中动

J Psychiatr Res:初诊抑郁症与动脉粥样硬化相关

  近期发表于《精神病学研究杂志》(J Psychiatr Res)上的一项研究表明,相比健康对照组,初诊抑郁症患者体内的血小板CD62P(P-选择素)、动脉粥样硬化标志物(CD40,CD40L)、血清血小板因子4(PF4)和β-血小板球蛋白(β-TG)水平会有所升高,说明抑郁症与血栓和炎症状态相关,而这可能会加速动脉粥样硬化。   炎症在动脉粥样硬化疾病中扮演重要角色。目前

Diabetes Care:T1DM增加青年动脉粥样硬化风险

1型糖尿病增加成人颈动脉内膜-中层厚度(IMT)。为了评价青年1型糖尿病患者的IMT,来自辛辛那提儿童医院和美国辛辛那提大学的Urbina博士等人进行了一项研究,研究发现青年1型糖尿病患者颈动脉IMT增厚。研究结果在线发表于2013年4月5日的美国《糖尿病护理》(Diabetes Care)杂志上。 研究对象为402例1型糖尿病参与者,以及经年龄、性别、种族和民族匹配的206例对照,参与者平均年

ARD:利妥昔单抗治疗可降低RA患者血清致动脉粥样硬化脂蛋白

致动脉粥样硬化血脂是心血管疾病(CV)的确定风险因素,而类风湿关节炎(CV)的高炎状态与不良血脂相关。新的免疫调节药物如利妥昔单抗(RTX)对血脂作用的数据有限。来自荷兰阿姆斯特丹UV大学医学中心的Hennie G Raterman等人对RTX治疗RA后患者血脂的变化进行了评估。研究结果发表在2013年4月的《风湿病学年鉴》(Ann Rheum Dis)杂志上。结果表明,RTX在改善疾病活动度的同